European medical regulators have given the thumbs up to the new AstraZeneca diabetes treatment . The drug, known as Onglyza, is a collab between the UK-based company and US group Bristol-Myers Squibb .
Onglyza (Saxagliptin) will be used to treat diabetes patients who have type 2 diabetes . It is designed to be used alone with diet and exercise, or used with metformin and other diabetes drugs to aid in blood sugar control .
The approval was based on research involving 4,000 diabetes patients and reportedly proved that the drug can significantly reduce blood sugar levels when added to regular diabetes treatments . The drug is one of the first DPP-4 inhibitors to be approved, and is also less likely to cause weight gain.
Thumbs up for new diabetes treatment
Tue, 06 Oct 2009
Recommended links
Diabetes financeDiabetes donate
Diabetes myLifestyle
Diabetes forum
The Diet Plate to help control diabetes
Risk of diabetes lowered by mothers milk
Centre for diabetes treatment is opened
New NICE diabetes treatment proposals
Hormone could aid diabetes treatment
Diabetes treatment progress
New stem cell treatment for diabetes could replace insulin
Bark could help in diabetes treatment
False diabetes treatments under investigation
Type 1 diabetes treatment breakthrough
Weekly injection could aid type 2 diabetes treatment
Gum disease treatment for diabetes patients
Join us